NeoGenomics
Forecast impact
Track in portfolio
Price chart
Description
Company and Business Model
NeoGenomics is a healthcare company specializing in cancer diagnostics and genomic testing services. Its core products include a range of molecular and genomic tests that assist in cancer diagnosis, treatment selection, and monitoring. Major business segments encompass clinical testing services and pharmaceutical services, with primary revenue sources derived from laboratory testing and partnerships with pharmaceutical companies for clinical trials.
Investment Profile
The investment profile of NeoGenomics suggests it may be more suitable for value investors, given its current pricing relative to earnings and growth potential. The stock exhibits characteristics that may appeal to those seeking a balanced approach, though it carries higher risk factors. Investors should consider the company's volatility and market position when evaluating their investment horizon.
Fundamental metrics (experimental) Updated: 2026-11-20
- EPS (TTM) — earnings per share for the last 12 months, $
- -0.25
- Revenue QoQ — quarter-over-quarter revenue growth
- 3.8%
- EPS surprise
- 26.2%
- 20d volatility
- 2.6%
- last ex-date
- 2020-12-17
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-11-14 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-10-31 | Sell | Hold | Weak fundamentals with mixed momentum signals. |
| 2026-10-23 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-10-15 | Sell | Hold | Weak fundamentals with mixed momentum signals. |
| 2026-10-07 | — | Sell | Weak fundamentals and negative momentum raise significant risk. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-29 | TD Cowen | Target Raised | 19 → 23 | 17.93 |
| 2026-10-29 | Jefferies | Target Raised | 16.5 → 21 | 17.0304 |
| 2026-10-06 | Needham | Target Raised | — → 22 | 19.13 |
| 2026-10-06 | BTIG | Update | — → 28 | 19.13 |
| 2026-07-29 | Craig-Hallum | Target Raised | 17 → 19 | 15.785 |
| 2026-04-29 | Leerink Partners | Update | — → 25 | 9.02 |
| 2026-02-24 | Piper Sandler | Target Raised | 12 → 13 | 9.97 |